Kovina Therapeutics Inc. announced receipt of a Small Business Innovation Research (SBIR) one-year Phase I award from the National Institute of Dental and Craniofacial Research (NIDCR/NIH)to treat oropharyngeal cancers caused by Human Papillomavirus (HPV) infections. The award provides approximately $275,000 with the opportunity for advancement to Phase 2.

Kovina Therapeutics Inc. announced receipt of a Small Business Innovation Research (SBIR) one-year Phase I award from the National Institute of Allergy and Infectious Diseases(NIAID)/NIH to treat Human Papillomavirus (HPV) premalignant infections. The award provides approximately $300,000 with the opportunity for advancement to Phase 2. ‍

Kovina Therapeutics Inc. announced receipt of a Fast-Track Small Business Technology Transfer (STTR) grant from the National Cancer Institute/NIH. With successful achievement of its milestones, the award will transition to a Small Business Innovation Research (SBIR) award and will provide approximately $2,400,000 over three years.

With the support of IU Ventures and the IU Innovation and Commercialization Office, Kovina Therapeutics, a preclinical biotechnology startup seeking to develop first-in-class antiviral therapies for Human Papillomavirus (HPV) related cancers and pre-cancerous malignancies, recently closed a $2 million seed round of financing.

Kovina Therapeutics announced the recent close of a $2 million seed round of financing led by Elevate Ventures. Kovina is a preclinical biotechnology company developing first-in-class antiviral therapies to treat cancers and pre-cancerous malignancies associated with Human Papillomavirus (HPV).